To retrospectively analyze postmenopausal patients with prolactinomas, evaluating outcomes of dopamine agonist withdrawal, including remission rates and recurrence, while characterizing clinical features and treatment responses.
Approach:
Key Findings:
The study represents the largest Chinese cohort investigating bromocriptine withdrawal in postmenopausal women, highlighting the need for further research.
Menopause may positively influence the disease course, with some patients maintaining remission after withdrawal, suggesting a potential shift in treatment approach.
Only five relevant studies on this topic have been reported to date, indicating a significant gap in research.
Interpretation:
The findings suggest that postmenopausal women with prolactinomas may have different treatment responses and outcomes, necessitating tailored management strategies that consider hormonal changes and individual patient profiles.
Limitations:
The study is retrospective and conducted at a single center, which may limit generalizability and introduce selection bias.
The precise prevalence of prolactinomas in postmenopausal women remains uncertain due to underdiagnosis and potential biases in retrospective studies.
Conclusion:
Further research is needed to develop standardized management strategies for postmenopausal women with prolactinomas, particularly regarding dopamine agonist withdrawal, including studies on long-term outcomes and patient quality of life.
